Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | 88.01% | 88.01% | -80.11% | -80.11% | |
| Total Depreciation and Amortization | -4.96% | -4.96% | -18.39% | -18.39% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -333.37% | -333.37% | 128.63% | 128.63% | |
| Change in Net Operating Assets | -412.18% | -412.18% | 1,278.18% | 1,278.18% | |
| Cash from Operations | -154.18% | -154.18% | -21.24% | -21.24% | |
| Capital Expenditure | -- | -- | -38.46% | -38.46% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -- | -- | -38.46% | -38.46% | |
| Total Debt Issued | 174.09% | 174.09% | -2.51% | -2.51% | |
| Total Debt Repaid | -236.80% | -236.80% | 0.00% | 0.00% | |
| Issuance of Common Stock | 108.35% | 108.35% | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | 460.60% | 460.60% | -5.39% | -5.39% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 4,611.30% | 4,611.30% | -199.58% | -199.58% | |